| Rank |
Status |
Study |
| 1 |
Recruiting
|
A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome
| Condition: |
Irritable Bowel Syndrome |
| Interventions: |
Drug: Pregabalin (Lyrica); Drug: Placebo |
| Outcome Measures: |
Primary aim: Collect preliminary data comparing effects of Pregabalin and placebo on abdominal pain/discomfort on bowel symptom score (BSS), overall BSS score, and adequate relief of irritable bowel syndrome (IBS) symptoms in patients with IBS; To compare the effect of Pregabalin and placebo on self-reported overall and individual BSS scores; compare effect of Pregabalin and placebo on adequate relief of IBS pain or discomfort at least 50% of the time; To compare effect of Pregabalin and placebo on overall and individual BSS scores; To compare the effect of Pregabalin and placebo on the proportion of patients with at least 3 point changes in 11 point pain and IBS scores |
|
| 2 |
Recruiting
|
A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder
| Condition: |
Obsessive-Compulsive Disorder |
| Interventions: |
Drug: pregabalin; Drug: Placebo |
| Outcome Measures: |
Yale-Brown-Obsessive-Compulsive-Scale; Clinical Global Impression - Improvement; Montgomery Asberg Depression Rating Scale; Sheehan Disability Scale; Beck Depression Inventory; Clinical Global Impression - Severity; Saving Inventory - Revised; Dimensional Yale-Brown-Obsessive Compulsive Scale (D-Y-BOCS); Padua Inventory |
|
| 3 |
Not yet recruiting
|
Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain
| Condition: |
Diabetic Neuropathy |
| Interventions: |
Drug: KW21052; Drug: Lyrica; Drug: Lyrica (low dose); Drug: Placebo of KW21052; Drug: Placebo of Lyrica |
| Outcome Measures: |
Numerical pain rating scale (NRS); Change on on the numerical pain rating scale (NRS); Response rate; Clinical Global Impression of Change (CGIC); Improved quality of life (QoL); Drug compliance; Adverse events |
|
| 4 |
Recruiting
|
The Effects of Pregabalin on Postoperative Pain After Cardiac Surgery
| Condition: |
Postoperative Pain |
| Interventions: |
Drug: Pregabalin 75mg; Drug: pregabalin 150 mg; Drug: Placebo |
| Outcome Measures: |
opioid consumption and other analgesics after surgery; Remaining surgery related pain and analgesics consumption |
|
| 5 |
Unknown †
|
Imipramine and Pregabalin Combination in Painful Polyneuropathy
| Condition: |
Polyneuropathy |
| Interventions: |
Drug: Imipramine; Drug: Pregabalin; Drug: Imipramine, pregabalin; Drug: Placebo |
| Outcome Measures: |
Total pain intensity as measured by numeric rating scale 0-10 points.; Verbal pain relief scale with 6 classes; Specific pain symptom rated by numeric rating scales 0-10 points; Rating of evoked pains symptoms (pressure, brush, repetitive pin-prick, cold) as measured by numeric rating scales 0-10 points; Sleep disturbance as measured by numeric rating scale 0-10 points; Consumption of escape medication (number of tablets of paracetamol); Health related quality of life (SF-36); Major Depression Inventory (MDI) |
|
| 6 |
Recruiting
|
A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis
| Conditions: |
Muscle Cramp; Liver Cirrhosis |
| Interventions: |
Drug: Pregabalin; Drug: Placebo |
| Outcome Measures: |
mean reduction rates of the frequency of muscle cramps between pregabalin and placebo groups; Response rates , Mean change in the average cramp pain intensity , peripheral nerve excitability , the quality of life, quality of sleep , safety |
|
| 7 |
Recruiting
|
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.
| Condition: |
Generalized Tonic Clonic Seizures |
| Interventions: |
Drug: Pregabalin Dose Level 1; Drug: Pregabalin Dose Level 2; Drug: Placebo |
| Outcome Measures: |
Percent reduction of 28 day seizure rate for all PGTC seizures relative to placebo during the double blind assessment phase.; Responder rate, defined as the proportion of subjects who had at least a 50% reduction in 28 day PGTC seizure. |
|
| 8 |
Unknown †
|
Efficacy of Pregabalin in the Management of Chronic Uremic Pruritus
| Condition: |
Uremic Pruritus |
| Interventions: |
Drug: Pregabalin; Drug: Placebo |
| Outcome Measures: |
Reduction of UP by more than 50% after Pregabalin administration; Reduction of chronic pain of various origin and improvement in insomnia after Pregabalin administration |
|
| 9 |
Recruiting
|
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
| Condition: |
Diabetic Neuropathy, Painful |
| Interventions: |
Drug: Pregabalin; Drug: Placebo matched with pregabalin |
| Outcome Measures: |
Endpoint mean pain score based on the pain scores from the subject's daily pain rating scale; Weekly mean pain scores from the subject's daily pain rating scale; Weekly mean sleep interference scores from the subject's daily sleep interference scale; Responder rates with at least a 30% reduction from baseline in weekly mean pain score; Change from baseline in Short-Form McGill Pain Questionnaire at week 9; Change from baseline in Pain Visual Analogue Scale at week 9; Change from baseline in Medical Outcomes Study -Sleep Scale at week 9; The Subject Global Impression of Change at week 9; The Clinical Global Impression of Change at week 9; Change from baseline in Hospital Anxiety and Depression Scale at week 9 |
|
| 10 |
Recruiting
|
Effects of Pregabalin on Post-cesarean Pain
| Condition: |
Uncomplicated Singleton Pregnancies |
| Interventions: |
Drug: Placebo; Drug: Pregabalin 300 mg group; Drug: Pregabalin 150 mg group |
| Outcome Measures: |
cumulative patient controlled morphine consumptions; postoperative pain scores; neonatal Apgar scores; Neurologic and adaptive capacity scores; Maternal sedation; Maternal nausea and vomiting |
|
| 11 |
Recruiting
|
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
| Condition: |
Diabetic Neuropathy, Painful; Diabetic Neuropathies |
| Interventions: |
Drug: AZD5213 + pregabalin; Drug: Placebo; Drug: pregabalin capsules |
| Outcome Measures: |
Change in Item 5 of Brief Pain Inventory Diabetic Peripheral Neuropathy version (BPI-DPN); Incidence and severity of Treatment Emergent Adverse Events; Vital signs ( blood pressure, heart rate, weight and temperature); Clinical Laboratory Evaluations; Medical Outcomes Study (Revised) Sleep Scale (MOS-R); Columbia Suicide Severity Rating Scale (CSSR-S); Neuropathic Pain Symptom Inventory (NPSI); Sleep Interference Scale (SIS) |
|
| 12 |
Unknown †
|
Perioperative Administration of Pregabalin for Pain After Septoplasty
| Condition: |
Deviated Nasal Septum |
| Interventions: |
Drug: Pregabalin (Lyrica); Drug: Vitamin complex (placebo) |
| Outcome Measures: |
Pain score (Verbal numerical rating scale, VNRS and Visual Analogue Scale, VAS); The number of patients with side effects including Nausea and vomiting, sedation, headache, dizziness; The number of patients who required additional analgesics during admission |
|
| 13 |
Not yet recruiting
|
Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain
| Conditions: |
Neuropathic Pain; Spinal Cord Injuries |
| Interventions: |
Drug: Pregabalin; Drug: Placebo |
| Outcome Measures: |
Daily at-level non-evoked pain intensity measured with the numerical rating scale (0-10) expressed as the mean 7-day pain intensity; Weekly below-level non-evoked pain intensity measured with the numerical rating scale (0-10); Weekly evaluation of at-level neuropathic pain symptoms using the "Neuropathic Pain Symptoms Inventory" (NPSI); Weekly evaluation of at-level neuropathic pain intensity and interference using the "Brief Pain Inventory" (BPI); Weekly evaluation of the change in at-level non-evoked neuropathic pain using the "Patient Global Impression Change" (PGIC); Weekly evaluation of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS); Weekly evaluation of spasm frequency below the spinal cord injury using the Penn questionnaire; Measurement of the amplitude of cold and heat sensory evoked potentials (Cz-Fz) studied above (C4) and at-level of the SCI; Serum TNF-R1 level; Weekly at-level non-evoked pain intensity measured with the numerical rating scale (0-10) 28 days after the termination of the clinical trial; Number of Paracetamol tablets used as rescue medication during the week; Prevalence and type of adverse events in patients treated with pregabalin; Unblinding testing: patient and investigator will be asked for the treatment they think to have received. Reasons for their judgement (efficacy and safety) will also be asked. |
|
| 14 |
Recruiting
|
Adolescent Fibromyalgia Study
| Condition: |
Fibromyalgia |
| Interventions: |
Drug: placebo; Drug: pregabalin (Lyrica) |
| Outcome Measures: |
Endpoint mean pain score from daily pain diary; Endpoint mean sleep quality score from the daily sleep diary; Pain Numeric Rating Scale (Pain-NRS) at Termination Visit; Patient Global Impression of Change at Termination; Parent Global Impression of Change at Termination Visit; Fibromyalgia Impact Questionnaire for Children at Termination Visit; Frequency and severity of adverse events at every visit.; Physical and neurological exams.; Vital signs.; Suicidality Tracking Scale (STS).; 12-Lead Electrocardiogram (ECG).; Laboratory tests: hematology, chemistry, serum pregnancy, urinalysis.; Reproductive hormone monitoring (females only); Tanner staging-assessment of pubertal status (females only); Pharmacokinetic endpoint: A population pharmacokinetic analysis will be performed using the sparse PK samples obtained at V6. |
|
| 15 |
Recruiting
|
Effect of Pregabalin in Patients With Radiation-Induced Peripheral Neuropathic Pain
| Condition: |
Neuropathic Pain |
| Interventions: |
Drug: Pregabalin; Drug: Placebo |
| Outcome Measures: |
Daily Pain Rating Scale (DPRS) at week 12; The modified Brief Pain Inventory-short form (mBPI); Daily Sleep Interference Scale(DSIS) |
|
| 16 |
Unknown †
|
Efficacy of Pre-operative Oral Pregabalin in Ambulatory Inguinal Hernia Repair for Post Operative Pain
| Conditions: |
Inguinal Hernia; Postoperative Pain |
| Intervention: |
Drug: Pregabalin |
| Outcome Measures: |
Study is constructed to determine whether the use of oral pregabalin premedication to assess the analgesic efficacy for post operative pain at Alert, 15, 30, 45, 60 and 120 min, Day 1, Day 2 and Day 3.; Opiod Sparing; Side effect of medication |
|
| 17 |
Not yet recruiting
|
Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia
| Conditions: |
Taxane; Drug-related Side Effects and Adverse Reactions; Pain; Breast Cancer |
| Interventions: |
Drug: Pregabalin; Drug: Placebo |
| Outcome Measures: |
Integrated Numeric Pain Scores and Rescue Analgesic Medication Requirement as calculated by the method proposed by Silverman et al (Silverman, O'Connor et al. 1993).; Numeric Pain Score (NPS); The additional number of hours spent in horizontal position (∆HHP**); FACT-taxane score |
|
| 18 |
Recruiting
|
Evaluation of Preoperative Use of Pregabalin on Postoperative Analgesia After Laparoscopic Colorectal Surgery
| Condition: |
Postoperative Pain |
| Interventions: |
Drug: Pregabalin; Drug: Placebo; Drug: Morphine |
| Outcome Measures: |
Postoperative opioid consumption; Postoperative pain; Side- effects; Chronic Pain; Hospital stay |
|
| 19 |
Unknown †
|
Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia
| Conditions: |
Critical Limb Ischemia; Arterial Occlusive Disease; Pain; Ischemia |
| Interventions: |
Drug: pregabalin; Drug: placebo |
| Outcome Measures: |
Reduction in Rating Scale (RS) pain compared to baseline. RS Pain will be assessed at 7, 14 days for all participants and after 28 and 56 days for patients continuing the extended phase of study.; Improvement in the Short Form 36 (SF-36) parameter "bodily pain".; The amount, dose and duration of concomitant pain medication use during study compared to use before study.; Safety outcomes and adverse events will be examined and recorded throughout the study. Patient reported dizziness will be recorded separately in the CRF, as well as blood pressure at visits. |
|
| 20 |
Unknown †
|
Pain Relief Following Arthroscopic Rotator Cuff Repair: Perioperative Pregabalin Administration Versus Interscalene Brachial Plexus Block
| Condition: |
Pain |
| Interventions: |
Drug: Pregabalin; Procedure: ISBPB - interscalene brachial plexus block |
| Outcome Measure: |
To compare postoperative pain relief by pregabalin versus ISBPB following arthroscopic rotator cuff repair |
|
